Form 4: Beyond Air Director Granted Stock Options

Beyond Air, Inc. Director Robert Scott Goodman was granted 3,750 stock options with an exercise price of $2.45, vesting over four years.

Summary

• Director Robert Scott Goodman of Beyond Air, Inc. (XAIR) was granted 3,750 stock options.
• The options have an exercise price of $2.45 per share.
• The grant date for these options is August 14, 2025.
• The options will vest over a four-year period, with 25% vesting on December 31, 2025, and the remainder vesting in equal annual installments on December 31 of the three subsequent years.
• The options expire on August 14, 2035.
• Following this transaction, Robert Scott Goodman beneficially owns 5,750 derivative securities (stock options), which includes the newly granted 3,750 options and an additional 2,000 stock split adjusted shares previously held.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns their interests with shareholders for long-term value creation. It's a standard compensation practice, indicating stability in governance, but doesn't inherently signal immediate operational improvements or financial breakthroughs.

Positives

• Granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued commitment from the director over several years.

Negatives

• The exercise price of $2.45 is a future price, and the value of these options depends on the stock price exceeding this amount in the future.

Risks

• The value of the stock options is contingent on the future performance of Beyond Air, Inc.'s stock price. If the stock price does not exceed the exercise price of $2.45, the options may expire worthless.
• Potential for dilution for existing shareholders if a significant number of options are exercised in the future, increasing the total outstanding shares.

Future Outlook

The grant of long-term stock options to a director suggests a strategic intent to align management incentives with the company's long-term growth and shareholder value creation.

Industry Context

The granting of stock options is a common practice in the biotechnology and medical device industries to attract and retain key talent, particularly in companies like Beyond Air, Inc. (XAIR) that are often in growth phases and rely on long-term innovation and market penetration.

Comparison to Industry Standards

• The vesting schedule of 25% after one year and then equal annual installments over three subsequent years is a standard four-year vesting period commonly observed in equity compensation plans across various industries, including biotech.
• Companies like Inovio Pharmaceuticals (INO) or Novavax (NVAX) often utilize similar long-term incentive structures for their executives and directors to ensure alignment with long-term strategic goals.

Stakeholder Impact

• Shareholders: Potential for long-term value alignment with the director, but also potential for minor dilution upon exercise of options.
• Management/Employees: Reinforces the company's use of equity-based compensation to incentivize key personnel.

Next Steps

• Monitoring the vesting of the stock options on December 31, 2025, and subsequent years.
• Observing any future exercises of these options by the director.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to a director, which is a standard compensation practice aimed at aligning long-term interests. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a catalyst for significant price movement or a re-evaluation of the company's fundamentals.

Keywords

Beyond Air, XAIR, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Executive Compensation, Insider Trading